Nykredit A/S’s Axsome Therapeutics AXSM Stock Holding History

Nykredit A/S’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$391K	Buy	+1,597	New	+$346K	﹤0.01%	762

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nykredit A/S's AXSM Position: Q2 2026 in Review

Nykredit A/S opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,597 shares worth $391K. The stake represents ﹤0.01% of the portfolio and ranks #762 among its holdings.

351 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Nykredit A/S held 1,597 shares of Axsome Therapeutics worth $391K as of Q2 2026.
Axsome Therapeutics was a new Nykredit A/S position in Q2 2026.
Axsome Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #762 holding.
351 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.